Nasdaq Watch the full interview
Justin Chen Li, CEO of Helio Genomics, sits down with Nasdaq's Kristina Ayanian to discuss how the AI-driven healthcare company is on a mission to save lives by developing technology that can detect cancer early from a simple blood draw.
In this conversation filmed live from the Nasdaq MarketSite, Helio Genomics' leadership outlines the company's core thesis: that the earliest signals of cancer can be read from cell-free DNA circulating in the blood, and that artificial intelligence is the key to interpreting those signals reliably and at scale.
"Our mission is simple — to save lives by detecting cancer early, from a simple blood draw. AI lets us see patterns in the genome that point to disease long before symptoms appear."
What the Interview Covers
The discussion spans the science and the strategy behind Helio Genomics — how the platform combines DNA methylation patterns with protein biomarkers, why early detection so dramatically changes outcomes for cancers like HCC, and how a blood-based approach can overcome the access and adherence barriers that limit traditional screening.
When cancer is found early, treatment options multiply and survival rates climb. Helio Genomics is building the technology to make that early window the norm rather than the exception.
Watch the full conversation on Nasdaq to hear the complete discussion on AI-driven diagnostics, the company's pipeline beyond liver cancer, and what comes next for blood-based early detection.
SOURCE Nasdaq